Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1075207 Target Snapshot

Transcriptional activator protein LasR · SINGLE PROTEIN · Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG12228)

235Compounds
105Assays
1Approved Drugs
140.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt P25084. Use UniProt P25084 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P25084 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Transcriptional activator protein LasR as ChEMBL target CHEMBL1075207, mapped to UniProt P25084. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Transcriptional activator protein LasR
SINGLE PROTEIN · Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG12228)
As of 2026-09-14
ChEMBL target ID
CHEMBL1075207
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P25084
Transcriptional activator protein LasR
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Transcriptional activator protein LasR is the right protein anchor across sources, using UniProt P25084 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTranscriptional activator protein LasR
UniProt AccessionP25084
Component TypeProtein
Sequence Length239 aa

Transcriptional activator protein LasR

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Transcriptional activator protein LasR, mapped to UniProt P25084. Sequence length is 239 aa.

Mapped IDP25084
Review nameTranscriptional activator protein LasR
OrganismPseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG12228)
Clinical Profile

Clinical Phase Distribution

1
Approved
Assay Mix

Activity Type Distribution

IC50100.0
EC5039.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL8483 8.82 EC50 1.507 Preclinical
CHEMBL1823931 8.81 EC50 1.532 Preclinical
CHEMBL3421671 8.44 EC50 3.6 Preclinical
CHEMBL1823932 8.0 EC50 10.0 Preclinical
CHEMBL8463 8.0 EC50 10.0 Preclinical
CHEMBL4283085 7.83 EC50 14.91 Preclinical
CHEMBL8450 7.82 EC50 15.0 Preclinical
CHEMBL1236450 7.55 EC50 28.0 Preclinical
CHEMBL1234965 7.53 EC50 29.66 Preclinical
CHEMBL1818523 7.52 IC50 30.0 Preclinical
Distribution

pChEMBL Value Distribution

15
5.0
14
5.5
9
6.0
9
6.5
6
7.0
8
7.5
5
8.0
2
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

105
Total Assays
80
Tested Compounds
2
Assay Types
Binding — 95 assays, 80 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 54 56 5.2
assay format 41 24 6.3
Functional — 10 assays, 20 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 10 20 6.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine